1. Home
  2. RZLT vs KMDA Comparison

RZLT vs KMDA Comparison

Compare RZLT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$4.47

Market Cap

420.8M

Sector

Health Care

ML Signal

HOLD

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$7.14

Market Cap

460.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
KMDA
Founded
2010
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
420.8M
460.3M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
RZLT
KMDA
Price
$4.47
$7.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$9.67
$14.00
AVG Volume (30 Days)
2.3M
33.0K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
3.08%
EPS Growth
26.32
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$13.94
Revenue Next Year
N/A
$9.84
P/E Ratio
N/A
$24.59
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$6.50
52 Week High
$11.46
$9.35

Technical Indicators

Market Signals
Indicator
RZLT
KMDA
Relative Strength Index (RSI) 46.19 42.20
Support Level $2.91 $7.00
Resistance Level $4.71 $7.16
Average True Range (ATR) 0.32 0.12
MACD -0.11 -0.01
Stochastic Oscillator 25.39 25.61

Price Performance

Historical Comparison
RZLT
KMDA

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: